[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hodgkins-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hodgkins-lymphoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,72,103,146,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100279415","phase-1-cd30-car-t-cells-relapsed-cd30-expressing-lymphoma-rely-30-100279415",false,"NCT02917083","CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30)","RELY-30","PROCUREMENT Inclusion Criteria:\n\n1. Diagnosis of relapsed\u002Frefractory HL or NHL.\n2. CD30 positive tumor as assayed in a CLIA certified pathology laboratory (result can be pending at this time)\n3. Hgb ≥ 7.0 (may be a transfused value)\n4. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n5. Karnofsky or Lansky score of \\> 60%\n\nTREATMENT Inclusion Criteria:\n\n1. Diagnosis of relapsed\u002Frefractory HL or NHL.\n2. CD30-positive tumor as assayed in a CLIA certified pathology laboratory.\n3. Age 16 to 75 for the first three patients on a dose level; thereafter, if no DLT, patients aged 12 to 75 can be treated on that dose level.\n4. Bilirubin 1.5 times or less than the upper limit of normal.\n5. AST 3 times or less than the upper limit of normal.\n6. Estimated GFR \\> 70 mL\u002Fmin.\n7. Pulse oximetry of \\> 90% on room air\n8. EKG shows no significant arrhythmias\n9. Karnofsky or Lansky score of \\> 60%.\n10. Available autologous T cells with greater than or equal to 15% expression of CD30CAR determined by flow-cytometry.\n11. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n12. Adequate pulmonary function with FEV1, FVC and DLCO (or DLCO\u002FVA, as clinically appropriate) greater than or equal to 50% of expected corrected for hemoglobin.\n13. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n14. Informed consent explained to, understood by and signed by patient or guardian.\n\nPROCUREMENT Exclusion Criteria:\n\n1. Active infection with HIV or HTLV (can be pending at this time).\n2. Active bacterial, fungal or viral infection.\n\nTREATMENT Exclusion Criteria:\n\n1. Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks.\n2. Received anti-CD30 antibody-based therapy within the previous 4 weeks.\n3. Subjects with rapidly progressive disease, defined as kinetic failure to previous chemotherapy.\n4. Bulky disease (defined as a 10 cm or greater mass or mediastinal disease with a transverse diameter exceeding 33% of the transthoracic diameter).\n5. History of hypersensitivity reactions to murine protein-containing products.\n6. Pregnant or lactating.\n7. Tumor in a location where enlargement could cause airway obstruction.\n8. Current use of systemic corticosteroids at a dose equivalent to 0.5 mg\u002Fkg\u002Fday of prednisone or higher.\n9. Active hemorrhagic cystitis.\n10. Active bacterial, viral or fungal infection.\n11. Symptomatic cardiac disease (NYHA Class III or IV disease).","ALL","12 Years","75 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The subject has a type of lymph gland cancer called Lymphoma.\n\nThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers; they both have shown promise, but have not been strong enough to cure most patients. Investigators hope that both will work better together.\n\nInvestigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. They now want to test whether these genetically modified T cells given after chemotherapy will be more effective at killing cancer cells.\n\nThe gene that will be put into the T cells makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients.\n\nFor this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric receptor-activated T cells (CD30.CAR T cells) seem to kill some of the tumor, but they don't last very long and so their chances of fighting the cancer are unknown.\n\nSeveral studies suggest that the infused T cells need room to be able to multiply and grow to accomplish their functions, and that this may not happen if there are too many other T cells in circulation. Because of that, doctors may use chemotherapy drugs to decrease the level of circulating T cells prior to the CD30.CAR T cells infusion. This is called \"lymphodepletion\"\n\nCD30.CAR T cells have previously been studied in lymphoma patients.",[28,29],"Hodgkin's Lymphoma","Non-Hodgkin Lymphoma",[31,32,33,34],"chimeric antigen receptors","immunotherapy","CAR T-cells","lymphoma","RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-10","ACTUAL",{"date":41,"type":39},"2017-05-08",{"date":43,"type":22},"2040-02",{"name":45,"class":46},"Baylor College of Medicine","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100466539","phase-2-a-phase-ii-study-of-the-combination-of-azacitidine-and-pembrolizumab-for-patients-relapsedrefractory-hodgkins-lymphoma-100466539","NCT05355051","A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed\u002FRefractory Hodgkin's Lymphoma","Inclusion Criteria:\n\n* HL patients with relapse or progression. Prior checkpoint inhibitors will be allowed\n* AML patients with relapse or progression. Patients may receive cytoreduction prior to enrollment for patients with rapidly proliferative disease before the start of study therapy, as needed, for clinical benefit and after discussion with the PI. Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted\n* Patients with relapsed HL involving extranodal sites\n* HL patients who are not regarded as a candidate for high-dose, conventional chemotherapy\n* Age of enrollment: Minimum age 1 year. No maximum age, study will include anyone in the pediatric\u002Fadolescent center\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 3 or Lansky performance status \\>= 50\n* Adequate renal function per age unless related to the disease\n* Adequate hepatic function including total bilirubin \\\u003C 2x upper limit of normal (ULN) unless increase is due to Gilbert's disease, and AST \\\u003C 3x ULN unless considered due to lymphoma involvement.\n* Provision of written informed consent or assent as per MDACC policy for study subjects.\n* Females must be surgically or biologically sterile or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment and each subsequent dose.\n* Women of childbearing potential must agree to use an adequate method of contraception during the study and until 4 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 1 month after the last treatment\n* Males need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment\n\nExclusion criteria:\n\n* Allergy to azacitidine or pembrolizumab or the drugs' components\n* Active and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III\u002FIV, clinically significant and uncontrolled arrhythmia as judged by the treating physician\n* Patients with known infection with human immunodeficiency virus (HIV) or active Hepatitis B or C\n* Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator\n* Pregnant or breastfeeding\n* Has received a live vaccine within 30 days of planned start study therapy\n* Current or prior use of immunosuppressive medication within 14 days prior to the first dose of pembrolizumab.\n\nThe following are exceptions to this criterion:\n\n* Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or equivalent\n* Steroids as premedication for hypersensitivity reactions (eg, computed tomography \\[CT\\] scan premedication)\n* As per Inclusion criteria #2\n\n  * Active or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener syndrome) within the past 2 years. Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded\n  * Has known active central nervous system metastases and\u002For carcinomatous meningitis",true,"1 Year",{"count":57,"type":22},24,[59],"PHASE2","This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed\u002Frefractory HL.",[28],"2026-05-14",{"date":64,"type":39},"2026-05-18",{"date":66,"type":39},"2022-10-05",{"date":68,"type":22},"2026-12-31",{"name":70,"class":46},"M.D. Anderson Cancer Center",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100193048","longitudinal-sexual-and-reproductive-health-study-of-women-with-breast-cancer-and-lymphoma-100193048","NCT01788839","Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma","Inclusion Criteria:\n\nSubject Inclusion Criteria for Cohort of Premenopausal Women with Early Stage Breast Cancer and Lymphoma\n\n* Women, 18 years of age and older\n* Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months\n\n  * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.\n* Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.\n* Breast cancer patients with any receptor type\n* English speaking\n* Able to participate in the informed consent process\n\nSubject Inclusion Criteria for Tamoxifen Only Subset of Cohort of Premenopausal Women with Early Stage Breast Cancer and Lymphoma\n\n* Women, 18 years of age and older.\n* Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months\n\n  * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.\n* Women with newly diagnosed breast cancer (stage 0-III) who have not yet started treatment and are planning to start Tamoxifen as their only form of systemic treatment within one month\n* Breast cancer patients with any receptor type\n* English speaking\n* Able to participate in the informed consent process\n\nSubject Inclusion Criteria for Cohort of Postmenopausal Women with Early Stage Breast Cancer and Lymphoma\n\n* Women, 18 years of age and older.\n* Postmenopausal women at time of diagnosis who have been without period for ≥ 2 years.\n* Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.\n* Breast cancer patients with any receptor type\n* English speaking\n* Able to participate in the informed consent process\n\nExclusion Criteria:\n\nSubject Exclusion Criteria for both Pre and Postmenopausal Women with Early Stage Breast Cancer and Lymphoma\n\n* Active secondary cancer requiring cytotoxic chemotherapy\n* Prior systemic treatment for a malignancy","FEMALE","18 Years",{"count":81,"type":22},475,"OBSERVATIONAL","The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.",[85,86,28],"Breast Cancer","Lymphoma",[88,89,90,91,92],"Sexual and Reproductive Health","premenopausal","postmenopausal","12-249","Fertility","2026-03-02",{"date":95,"type":39},"2026-03-04",{"date":97,"type":4},"2013-02",{"date":99,"type":22},"2027-02",{"name":101,"class":46},"Memorial Sloan Kettering Cancer Center",7,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":19,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":125,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":145},"100484580","phase-1-a-first-in-human-study-of-hla-partially-to-fully-matched-allogenic-cryopreserved-deceased-donor-bone-marrow-transplantation-for-patients-with-hematologic-malignancies-100484580","NCT05589896","A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Patient has the ability to provide informed consent according to the applicable regulatory and local institutional requirements\n* Male or female, aged ≥18 and ≤65 years for patients receiving MAC (Regimen A or Regimen B); aged ≥18 and ≤75 years for patients receiving RIC (Regimen C or D)\n* Patient must require allogeneic HCT per the discretion of the treating physician\n* Patient must be high-resolution, HLA partially or fully matched (4-8\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an available Ossium HPC, Marrow product\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Diagnosed with malignant hematologic disease including:\n\n  1. Acute leukemia \\[acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute biophenotypic leukemia (ABL), or acute undifferentiated leukemia (AUL)\\], MDS without fibrosis, or chronic leukemia (CLL, CML) in the first remission or beyond with ≤5% marrow blasts documented by bone marrow assessment and no circulating blasts or extra-medullary disease within 42 days prior to anticipated start of conditioning\n  2. Chemosensitive non-Hodgkin's lymphomas, Hodgkin's lymphoma, or cutaneous T cell lymphomas in the first remission or beyond documented by PET\u002FCT imaging and bone marrow assessment within 42 days prior to anticipated start of conditioning\n* Karnofsky performance status score ≥70% (MAC) or ≥60% (RIC)\n* HCT comorbidity index (HCT-CI) ≤5\n* Adequate organ function defined as:\n\n  1. Cardiac: LVEF at rest ≥40% (RIC) or LVEF at rest ≥45% (MAC)\n  2. Pulmonary: DLCO, FEV1, FVC ≥50% predicted by pulmonary function tests (PFTs). DLCO value may be corrected for hemoglobin.\n  3. Hepatic: total bilirubin ≤2.0 mg\u002FdL, and ALT, AST, and ALP \\\u003C3 x upper limit normal (ULN), unless ALT, AST, and\u002For ALP are disease related\n  4. Renal: SCr within 1.5x normal range for age. If SCr is outside normal range for age, CrCl\\> 60 mL\u002Fmin\u002F1.73m2 must be obtained (measured by 24-hour urine specimen or nuclear glomerular filtration rate (GFR), or calculated GFR)\n\nExclusion Criteria:\n\n* Availability of suitable graft from living donor (defined as 7\u002F8 or 8\u002F8 HLA-matched related or unrelated donors, haploidentical donors, or cord blood donors)\n* Prior autologous or allogeneic HCT\n* Pregnancy or lactation\n* Ongoing treatment with an investigational drug used for disease-related treatment within 5 half-lives of the drug\n* Current uncontrolled bacterial, viral or fungal infection defined as currently taking medication with evidence of progression of clinical symptoms or radiologic findings\n* Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that in the investigator's opinion precludes participation",{"count":110,"type":22},12,[25,59],"The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.",[114,115,116,117,118,119,120,121,122,123,124],"Acute Leukemia","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Acute Biphenotypic Leukemia","Acute Undifferentiated Leukemia","CLL (Chronic Lymphocytic Leukemia)","Chronic Myeloid Leukemia (CML)","MDS (Myelodysplastic Syndrome)","Non-Hodgkin Lymphomas","Hodgkins Lymphoma","Cutaneous T Cell Lymphomas (CTCL)",[126,127,17,128,129,130,131,86,132,133,134],"Leukemia","Hematologic Diseases","AML","ABL","AUL","Bone Marrow Transplant","MDS","CLL","CML","2026-02-20",{"date":137,"type":39},"2026-02-24",{"date":139,"type":39},"2024-08-16",{"date":141,"type":22},"2027-03-31",{"name":143,"class":144},"Ossium Health, Inc.","INDUSTRY",9,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":19,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":71},"100554075","phase-1-a-study-of-lcar-hl30-in-subjects-with-relapsedrefractory-hodgkins-lymphoma-and-anaplastic-large-cell-lymphoma-100554075","NCT06494371","A Study of LCAR-HL30 in Subjects With Relapsed\u002FRefractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma","An Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of CD30-Targeted LCAR-HL30 Cells in Patients With Relapsed\u002FRefractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma","Inclusion Criteria:\n\n1. Subjects voluntarily participate in clinical research.\n2. Aged 18 to 75 years, either sex.\n3. Eastern Cooperative Oncology Group (ECOG) score 0-1 (Dose escalation phase). ECOG score 0-2 (Dose expansion period).\n4. Histologically confirmed Hodgkin's lymphoma or Anaplastic large cell lymphoma with positive CD30 expression.\n5. At least one evaluable tumor lesion according to Lugano 2014 criteria.\n6. Expected survival ≥3 months.\n7. Clinical laboratory values in the screening period meet criteria.\n8. Effective contraception.\n\nExclusion Criteria:\n\n1. Prior antitumor therapy with insufficient washout period.\n2. Previous treatment with CAR-T therapy, allogeneic hematopoietic stem cell transplantation.\n3. Severe underlying diseases;\n4. Hepatitis B virus surface antigen (HbsAg), Hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C virus ribonucleic acid (HCV RNA) or human immunodeficiency virus antibody (HIV-Ab) positive.\n5. Presence of other serious pre-existing medical conditions that may limit patient participation in the study. Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.",{"count":154,"type":22},32,[25],"This is a prospective, single-arm, open-label, exploratory clinical study of LCAR-HL30 in adult subjects with relapsed\u002Frefractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma.",[28,158],"Anaplastic Large Cell Lymphoma",[28,158],"2024-07-04",{"date":162,"type":39},"2024-07-10",{"date":164,"type":22},"2024-07",{"date":166,"type":22},"2028-08",{"name":168,"class":46},"Ruijin Hospital",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":71},"100229052","phase-1-cd30-directed-chimeric-antigen-receptor-t-cart30-therapy-in-relapsed-and-refractory-cd30-positive-lymphomas-100229052","NCT02259556","CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas","CART30","Inclusion Criteria:\n\n* Male and female subjects with CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or refractory to 2 multidrug regimens and\u002For anti-CD30 antibody treatment.\n* Newly diagnosed CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma patients who are unable to receive or complete standard chemotherapy.\n* Karnofsky or Lansky score greater than 60%.\n* Expected survival\\>12 weeks.\n* Creatinine\\\u003C2.5mg\u002Fdl.\n* ALT (alanine aminotransferase)\u002FAST (aspartate aminotransferase)\\\u003C3 fold normal.\n* Bilirubin\\\u003C2.5mg\u002Fdl.\n* Pulse oximetry of \\>90% on room air.\n* Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of expected corrected for hemoglobin.\n* Available autologous T cells with 10% or more expression of CD30 CAR determined by flow-cytometry.\n* Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form.\n\nExclusion Criteria:\n\n* Active infection such as hepatitis B or C.\n* Receive anti-CD30 antibody-based therapy within recent 6 weeks.\n* Current use of systemic corticosteroids.\n* Pregnant or lactating.\n* Confirmed tumor in pulmonary and archenteric tissues.","16 Years","80 Years",{"count":179,"type":22},30,[25,59],"Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors. In this trial, CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma will be treated by CD30-specific CART cells (CART30).",[28,183],"Non-Hodgkin's Lymphoma","2016-01-26",{"date":186,"type":22},"2016-01-28",{"date":188,"type":4},"2014-10",{"date":190,"type":22},"2029-10",{"name":192,"class":46},"Chinese PLA General Hospital"]